ProfileGDS5678 / 1451466_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 78% 79% 86% 80% 82% 81% 78% 80% 78% 76% 80% 76% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9429875
GSM967853U87-EV human glioblastoma xenograft - Control 25.3500778
GSM967854U87-EV human glioblastoma xenograft - Control 35.5543379
GSM967855U87-EV human glioblastoma xenograft - Control 46.7509786
GSM967856U87-EV human glioblastoma xenograft - Control 55.6672280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7906282
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7053381
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3735378
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5890280
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4470478
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0405776
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6503980
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0528176
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.479779